9th INTERNATIONAL CONFERENCE OF ANTICANCER RESEARCH
6-10 October 2014, Porto Carras, Sithonia, Greece
www.iiar-anticancer.org

Under the auspices of:
The Union for International Cancer Control (UICC)
The Asian and Pacific Federation of Clinical Biochemistry (APFCB)
The Asian Pacific Organization for Cancer Prevention (APOCP)
The Austrian Society for Radiation Oncology (ÖGRO)
The European Group on Tumor Markers (EGTM)
The Hungarian Society of Epidemiology
The International Cancer Microenvironment Society (ICMS)
The International Geriatric Radiotherapy Group (IGRG)
The International Institute of Anticancer Research (IIAR)
The International Society for Biological and Environmental Repositories (ISBER)
The International Society of Oncology and Biomarkers (ISOBM)
The Italian Society of Uro-Oncology (SIUrO)
The Latinamerican and Caribbean Society of Medical Oncology (SLACOM)
The Lithuanian Society of Radiation Oncology (LSRT)
The North-Eastern German Society of Gynecological Oncology (NOGGO)
The Polish Society of Radiation Oncology (PSTRO)
The Portuguese Society of Radiotherapy - Oncology (SPRO)
The Society of Biotherapeutic Approaches, Japan
The Szeged Foundation for Cancer Research, Hungary
The Turkish Society for Electron Microscopy (TSEM)

Supported by:
The International Institute of Anticancer Research

Deadline for registration: September 26, 2014.
Deadline for submission of abstracts: August 10, 2014.

Dates and Venue
The 9th International Conference of Anticancer Research will be held at the Porto Carras Grand Resort, Sithonia, Halkidiki, Greece, from 6 to 10 October, 2014.

General Policy
The purpose of the Anticancer Research Conferences is to exchange scientific information worldwide and to discuss recent advances in both broad and specialized areas of experimental and clinical cancer research. International Scientific and Medical Societies are invited to participate in the Conference by organizing specialized sessions. This initiative presents a forum for inter-Society communication allowing the organization and coordination of international activities on cancer. Special sessions will be devoted to the discussion and arrangement of international cooperation projects and activities, encompassing the aims of the International Institute of Anticancer Research.

The Conference is organized and supported by the International Institute of Anticancer Research.

The Scientific Program will comprise of oral (10, 15, 30 or 40 minutes) and poster presentations. Both overviews and original works will be presented. Each oral presentation will be allocated a five-minute discussion time. Six conference rooms will be used simultaneously. Posters will be exhibited for 1-2 days. Projection facilities for PowerPoint presentations will be provided.
Organizing Committee

P.A. Abrahamsson, Malmö, Sweden
N. Agnantis, Ioannina, Greece
F.E. Ahmed, Greenville, NC, USA
C. Alexiou, Erlangen, Germany
L. Amaral, Lisbon, Portugal
F.L. Ampil, Shreveport, LA, USA
R. Andersson, Lund, Sweden
S. Arbak, Istanbul, Turkey
V. Barak, Jerusalem, Israel
D.T. Bau, Taichung, Taiwan
G. Bauer, Freiburg, Germany
A. Bishayee, Signal Hill, CA, USA
R. Bjerkvig, Bergen, Norway
G. Broich, Monza, Italy
C. Carlberg, Kuopio, Finland
G. Bauer, Freiburg, Germany
A.F. Gazdar, Dallas, TX, USA
R. Friedrich, Hamburg, Germany
M. Friedrich, Krefeld, Germany
J.W. Greiner, Bethesda, MD, USA
F. Guadagni, Rome, Italy
C. Haste, Guildford, Surrey, UK
J. Hau, Copenhagen, Denmark
R. Hoffman, San Diego, CA, USA
S. Holderrieder, Bonn, Germany
T. Ibir, Istanbul, Turkey
S. Jhanwar, New York, NY, USA
M. Jhanwar-Unjyal, New York, NY, USA
B. Kaina, Mainz, Germany
E. Kandil, New Orleans, LA, USA
D.G. Kieback, Riesa (Dresden), Germany
I. Kiss, Pécs, Hungary
R. Klapdor, Hamburg, Germany
R. Knecht, Hamburg, Germany
M. Kohonen-Corish, Sydney, NSW, Australia
M. Koutsilieris, Athens, Greece
K. Kubota, Mibu, Tochigi, Japan
S. Kumar, Manchester, UK
P.M. Kumar, Manchester, UK
O.D. Lærum, Bergen, Norway
S.A. Lammrech, Beer-Sheva, Israel
W. Lichtenegger, Berlin, Germany
D. Lincoln, Chapel Hill, QLD, Australia
B. Littlefield, Andover, MA, USA
F. Lunachi, Padova, Italy
S. Mitra, Galveston, TX, USA
R. Molina, Barcelona, Spain
J. Molnár, Szeged, Hungary
N. Motohashi, Tokyo, Japan
R.M. Nagler, Haifa, Israel
N. Nguyen, Tucson, AZ, USA
C. Nicolini, Genova, Italy
C. Pace-Aciak, Toronto, ON, Canada
S. Pathak, Houston, TX, USA
G.J. Pilkington, Portsmouth, UK
C.D. Plakoucas, Norfolk, VA, USA
A. Pollack, Jerusalem, Israel
J. Reichrath, Homburg/Saar, Germany
D.A. Ribeiro, Santos, SP, Brazil
M. Rigaud, Limoges, France
F.M. Robertson, Houston, TX, USA
M. Roselli, Rome, Italy
G.R. Rutteman, Utrecht, Netherlands
C. Sansom, London, UK
S. Sarkar, Boston, MA, USA
A. Schauer, Göttingen, Germany
D. Schiffer, Verceil, Italy
J. Schneider, Alcortín (Madrid) Spain
M. Schneider, Wuppertal, Germany
O.J. Semmes, Norfolk, VA, USA
A. Seth, Toronto, ON, Canada
G. Sica, Rome, Italy
J. Slansky, Denver, CO, USA
K. Smetana, Prague, Czech Republic
S.S. Smith, Duarte, CA, USA
R.M. Snapka, Columbus, OH, USA
J. Sterling, Nashville, TN, USA
T. Stigbrand, Umeå, Sweden
K. Syrjäläinen, Helsinki, Finland
R.T. Todora, Sofia, Bulgaria
O. Topolcan, Pilsen, Czech Republic
G.C. Torre, Finale Ligure (SV), Italy
V. Treska, Pilsen, Czech Republic
M.de L.G. Trigo, Porto, Portugal
G. Tsangaris, Athens, Greece
E. Vairaktaris, Athens, Greece
D. Vesely, Tampa, FL, USA
D. Vetcikova, Prague, Czech Republic
J.K. Vishwanatha, Fort Worth, TX, USA
G. Vollmer, Dresden, Germany
A. Wani, Columbus, OH, USA
I.P. Witz, Tel Aviv, Israel
Y. Yen, Duarte, CA, USA
C.H. Yip, Petaling Jaya, Malaysia
O. Zoras, Heraklion, Greece

Scientific Program

Experimental Research Sessions

1. Oncogenes; tumor suppressor genes; growth factors; signal transduction.
3. Cancer stem cells.
7. Cancer systems biology and signaling.
11. Invasion and metastasis.
12. Cytogenetics and genetics.
13. Epigenetics.
14. Tumor angiogenesis and anti-angiogenesis.
17. Tumor microenvironment; cell–cell interactions; adhesion; stroma; cancer-associated fibroblasts.
20. Natural production in cancer drug development.
21. Experimental chemotherapy.
22. Immunobiology of cancer.
23. Gene therapy.

Clinical Research Sessions

25. Diagnosis and prognosis of cancer.
27. Serum markers.
28. Clinical chemotherapy.
29. Immunotherapy; biotherapy; vaccines.
30. Hormone therapy.
31. Radiotherapy.
32. Hyperthermia.
33. Personalized medicine in cancer.
34. Advances in breast cancer.
35. Advances in gynecologic cancer.
36. Advances in prostate cancer.
37. Advances in neurooncology.
38. Advances in colorectal cancer.
40. Advances in gastrointestinal cancer.
41. Advances in hemato-oncology.
42. Melanoma: New therapies and biomarkers.
44. Epidemiology.
46. Special symposia.
Publications

Abstracts of all contributed papers will be published in a special issue of ANTICANCER RESEARCH, which will be distributed to registrants during the Conference, as well as to all subscribing libraries and indexing services (print and online through the Stanford University HighWire Press). After recommendation by the Organizing Committee, selected contributions will be invited as complete original papers or reviews to be submitted for publication in ANTICANCER RESEARCH. Paper submissions will also be welcome during the Conference.

Abstracts (titles and authors) will be announced in www.iiar-anticancer.org upon acceptance. The final conference program will be publicised on September 10, 2014.

Registration

– Registration is required of all participants.
– Registration deadline: 26 September, 2014.
– Registration fee: EURO 260.00; Students, EURO 140.00; accompanying person, EURO 100.00 (each); Children, no fee.
– The registration fee for the Conference participants partially covers: attendance at the scientific sessions; all Conference material and documentation (final program, list of participants, book of Abstracts, Conference folder, Certificate of attendance and registration badge) from the Conference Secretariat; participation in all social events (social dinners, guitar recital, coffee breaks, closing gala dinner), and conference gifts.
– The registration fee for accompanying persons covers: participation in all social events; eligibility for special accommodation fees (the same offer that apply to Conference participants).
– The registration fee for the Members of the auspicious societies is waived.
– Registration will be regarded as final only after all forms and registration plus accommodation fees have been received by the Editorial Office of Anticancer Research.

Accommodation

Hotel reservation requests should be submitted directly to the Editorial Office of Anticancer Research. The Porto Carras Grand Resort (★★★★★) is located in a beautiful, peaceful setting by the sea and will provide excellent service and quality half-board accommodation for all participants.

● Accommodation fees:
  – Double room: EURO 66.00 per person, per day.
  – Single room: EURO 98.00 per person, per day.
  – Children 2-12 years old as 3rd person in double room: EURO 35.00.
The fee covers: accommodation in A (★★★★★) type rooms (bath, balcony, radio, TV, telephone), breakfast, dinner and transportation from and to the Airport of Thessaloniki on October 5 and October 11, 2014, respectively.

● Service hours: Breakfast (buffet): 7.30 – 10.00 a.m.; Dinner (formal club style) 19.00 – 22.30 p.m.; Self-service restaurant for lunch: 12.30 – 14.00 p.m.
● Accommodation requests are valid if made through the official conference Registration Form. For accommodation & registration to be secured all fees need to have been paid in advance.
● Cancellations: Abstract and registration plus accommodation fees will be returned if participation is cancelled before August 10, 2014. No refunds will be offered past this date.

Travel Arrangements

The Conference will officially commence on the morning of October 6, 2014. Therefore, participants should preferably arrive on October 5, 2014. The conference will conclude with the closing gala dinner on October 6, 2014. Participants are advised to finalize their travel plans at the earliest possible date. Details of date, flight number and time of arrival at Thessaloniki Airport should be given to the Editorial Office not later than September 26, 2014.

Aegean Airlines: www.aeganair.com
Olympic Airways: www.olympicairlines.com

Airport – Hotel Transportation

Shuttle buses will provide transportation from Thessaloniki Airport to the Hotel only on Sunday, October 5, 2014, and from the Hotel to the airport only on Saturday, October 11, 2014. Participants will be welcomed at the airport by a conference representative. Participants arriving on days other than October 5 or departing on days other than October 11 will have to hire a taxi (50 min, Euro ~120) at their own expense.

Weather

October is a very pleasant month in Sithonia, Greece. The average temperature is 24˚C (range 20-30˚C).

Instructions for Submitting an Abstract

1. Only abstracts containing new results (original research work or overviews) will be accepted. Abstracts should clearly and adequately describe the objectives and results of the research. All abstracts must be submitted in English.
2. All abstracts need to be accompanied by a completed Conference Registration Form made out in the name of the Author presenting the paper.
   a. Each abstract should include a title (in capital letters), names of all authors (with the name of the author who will be presenting the paper underlined), as well as complete address(es).
   b. Two types of abstracts may be submitted:
      ● Short abstract, not exceeding 300 words.
      ● Long abstracts not exceeding 1500 words, with 1-2 figures or tables (max size 8 cm width x 12 cm height), including abstract, introduction, materials and methods, results, discussion, acknowledgements, references. Color figures will be charged 180.00 EURO per page.
   c. Careful typing and proof-reading are essential.
   d. Abstract forms will not be provided.
3. Abstracts and a completed Conference Registration Form should be sent to: Dr. John G. Delinasios, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd, P.O. Box 22, Kapandriti 19014, Greece.
   E-mail: journals@iiar-anticancer.org.

   Abstracts must arrive at our offices by August 10, 2014, at the latest.
4. A reply (regarding decision, acceptance or revision) will reach the author within 5-12 days from submission.

Instructions for Poster Presentations

Abstracts scheduled for presentation in poster sessions will be grouped by topic, numbered and listed in the program, and published in the Abstract Book, as well as in ANTICANCER RESEARCH. Posters will be exhibited for 1-2 days and program listings will specify the time for poster discussion.

The original abstract of each poster presentation should arrive by August 10, 2014, at the latest at our offices. For the preparation of the abstract, please follow the Instructions for Submitting an Abstract.

The poster board surface area is 0.64 m² [0.8 m (31.5 inches) high and 0.8 m (31.5 inches) wide]. Poster presentations should include:
   title, authors, institutional affiliation, abstract, short introduction, methods, results, discussion, references and conclusion.
CONFERENCE REGISTRATION FORM

☐ Please reserve my place at the 9th International Conference of Anticancer Research.
☐ I shall be accompanied by ............. adults and ............. children.
   (Please complete separate forms for each accompanying person.)
☐ I plan to present ............. poster(s). Topic number .............
☐ I plan to present ............. oral communication(s): ............. minutes. Topic Number .............
☐ Abstract is attached. (Please follow the instructions for submitting an abstract).
☐ I shall require accommodation in single ☐ or double ☐ room;
   Accommodation fees: Double room, EURO 66.00 per person per night; Single room, EURO 98.00 per person per night;
   Children 2-12 years old, as 3rd person in the same room, EURO 35.00.
   The fee covers accommodation in 5*-type rooms, breakfast, dinner, transportation from and to Thessaloniki Airport.
   Registration fee: EURO 260.00; Students, EURO 100.00; Accompanying person, EURO 100.00.

☐ Registration fee is enclosed. Accommodation fee for ............. nights is also enclosed.
   (Cheques should be made payable to Delinasios G.J. & CO G.P., Athens, Greece. Credit cards are NOT accepted.)
☐ Please send an invoice for EURO ............. (and instructions for payment).
☐ I am a student (certificate enclosed).
☐ I will require transportation between Thessaloniki Airport and the Porto Carras Hotels on October 5 and 11, 2014.
   Time of my arrival: ............. Flight no.: .............
   Time of my departure: ............. Flight no.: .............
☐ Please enter my personal subscription to Anticancer Research/IN VIVO/2015 (including all previous volumes online) at the special conference rate. ☐ online (EURO 200.00); ☐ print & online (EURO 300.00).

Title: ..............................................................................................................................................................
Name: .........................................................................................................................................................
   Sex: male ☐ or female ☐
Institution (or Company): ...............................................................................................................................
Address: ......................................................................................................................................................
Tel: .........................................................................................................................................................
Fax: .........................................................................................................................................................
E-mail: .....................................................................................................................................................

Deadline for registration: September 26, 2014.
Deadline for submission of abstracts: 10 August, 2014.

Please mail completed form and Registration & Accommodation fees to:
Dr. John G. Delinasios, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti 19014, Greece.
Tel. / Fax: +30 22950 53389; e-mail: conference@iiar-anticancer.org. Website: www.iiar-anticancer.org
Please photocopy for additional forms.
ANTICANCER RESEARCH is an independent international forum devoted to the rapid publication of original high quality articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months from acceptance are guaranteed.

ANTICANCER RESEARCH is published monthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press.

For more information please visit our website www.ar.iiarjournals.org.

Editorial Office: International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19104, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org. IIAR website: www.iiar-anticancer.org

Selection of Recent Articles


LATS2 Is a Modulator of Estrogen Receptor Alpha. L.C. LIT, S. SCOTT, H. ZHANG, J. STEBBING, A. PHOTIOU, G. GIAMAS (London, UK)


Pre- and Postoperative Treatment Modalities for Esophageal Squamous Cell Carcinoma. C.M.R. THALLINGER, B. KIESEWETTER, M. RADERER, M. HEJNA (Vienna, Austria)

Utility of Hypertension as a Surrogate Marker for Efficacy of Antiangiogenic Therapy in NSCLC. T. EVANS (Philadelphia, PA, USA)

Biomarkers of Pituitary Neoplasms. A. SAV, F. ROTONDO, L.V. SYRO, B.W. SCHEITHAUER, K. KOVACS (Istanbul, Turkey; Toronto, ON, Canada; Medellin, Colombia; Rochester, MN, USA)

Recognition of a Natural WT1 Epitope by a Modified WT1 Peptide-specific T-Cell Receptor. T. TAMANAKA, Y. OKA, F. FUJIKI, A. TSUBOI, A. KATSUHARA, H. NAKAJIMA, N. HOSEN, S. NISHIDA, Y.-H. LIN, S. TACHINO, Y. AKATSUKA, K. KUZUSHIMA, Y. OJI, A. KUMANOGOH, H. SUGIYAMA (Osaka; Toyoake; Nagoya, Japan)

Antitumor Effects of Synthetic 6,7-Annulated-4-substituted Indole Compounds in L1210 Leukemic Cells In Vitro. J.-P.H. PERCHELLE T, A.M. WATERS, E.M. PERCHELLET, P.D. THORNTON, N. BROWN, D. HILL, B. NEUENSWANDER, G.H. LUSHINGTON, C. SANTINI, N. CHANDRASOMA, K.R. BUSZEK (Manhattan; Lawrence; KS; Kansas City, MO, USA)


Nutrition in Adult and Childhood Cancer: Role of Carcinogens and Anti-carcinogens. T.T. MOSBY, M. COSGROVE, S. SARKARDEI, K.L. PLATT, B. KAINA (Memphis, TN, USA; Mainz, Germany)

Successful Rechallenge for Oxaliplatin Hypersensitivity Reactions in Patients with Metastatic Colorectal Cancer. T. YANAI, S. IWASA, H. HASHIMOTO, K. KATO, T. HAMAGUCHI, Y. YAMADA, Y. SHIMADA, H. YAMAMOTO (Tokyo, Japan)


Glucocorticoids Augment Survival and Proliferation of Tumor Cells. S. GÖNDISCH, E. BOECKLER, U. BEHRENDTS, E. AMTMANN, H. EHRHARDT, I. JEREMIAS (Munich; Heidelberg, Germany)


siPGK1 Sensitizes Chemoresistant Human Ovarian Cancer Cell Lines to Cisplatin. C. LEUPLEX, E. ABEILARD-LEMOISSON, M. DUVAL, P. ICARD, H. LINCHET (Caen, France)

Immunohistochemical Expression of PTTG in Brain Tumors. F. SALEHI, B.W. SCHEITHAUER, S. SHARMA, K. KOVACS, R.V. LLOYD, M.D. CUSIMANO, D.G. MUNOZ (Toronto, ON, Canada; Rochester, MN, USA)

Silencing of The ARP2/3 Complex Disturbs Pancreatic Cancer Cell Migration. H.E. RAUHALA, S. TEPPO, S. NIEMELÄ, A. KALLIONIEMI (Tampere, Finland)

Anticancer Efficacy of the Metabolic Blocker 3-Bromopyruvate: Specific Molecular Targeting. S. GANAPATHY-KANNIAPPAN, R. KUNJITHAPATHAM, J.-F. GESCHWIND (Baltimore, MD, USA)

Characterization of Multiple Myeloma Clonal Cell Expansion and Stromal Wnt/β-catenin Signaling in Hyaluronic Acid-based 3D Hydrogel. N.K. NARAYANAN, B. DUAN, J.T. BUTCHER, A. MAZUMDER, B.A. NARAYANAN (Tuxedo; Ithaca; New York, NY, USA) .......................................................... 67

A New Biometric Tool for Three-Dimensional Subcutaneous Tumor Scanning in Mice. G. BOCCI, F. BUFFA, B. CANU, R. CONCU, A. FIORAVANTI, P. ORLANDI, T. PISANU (Pisa; Cagliari; Florence, Italy) ........................................................................................................................................................ 75

Investigation of Necessity of Sodium Cholate and Minimal Required Amount of Cholesterol for Dietary Induction of Atherosclerosis in Microminipigs. K. AKIOKA, H. KAWAGUCHI, S. KITAJIMA, N. MIURA, M. NOGUCHI, M. HORIZUCHI, N. MIYOSHI, A. TANIMOTO (Kagoshima, Japan) ........................................................................................................... 81

An Infrared Spectroscopic Study of Aortic Valve. A Possible Mechanism of Calcification and the Role of Magnesium Salts. V. DRITSA, K. PISSARID, E. KOUTULAKIS, I. MAMARELIS, C. KOTOULAS, J. ANASTASSOPOULOU (Athens, Greece) .............................................................. 91

Clinical Studies

Activated Partial Thromboplastin Time Correlates with Methoxyhydroxyphenylglycol in Acute Myocardial Infarction Patients: Therapeutic Implications for Patients at Cardiovascular Risk. A. PINELLI, S. TRIVULZIO, G. ROSSONI (Milan, Italy) .................................................................................................................. 99

MMP7 Expression in Colorectal Tumours of Different Stages. A. POLISTENA, A. CUCINA, S. DINICOLA, C. STENE, G. CAVALLARO, A. CIARDI, G. ORLANDO, R. ARENA, G. D’ERMO, A. CAVALLARO, L.B. JOHNSON, G. DE TOMA (Rome, Italy; Malmö, Sweden) ................................................................................................. 105

Full High-definition Three-dimensional Gynaecological Laparoscopy – Clinical Assessment of a New Robot-assisted Device. B. TUSCHY, S. BERLIT, J. BRADE, M. SÜTTERLIN, A. HORNEMANN (Mannheim, Germany) .................................................................................................................. 111


The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study. M. SCALA, P. MEREU, F. SPAGNOLO, M. MASSA, A. BARLA, S. MOSCI, G. FORNO, A. INGENITO, P. STRADA (Genoa, Italy) .................................................................................................................. 121

Pseudoepitheliomatous Hyperplasia Associated with Bisphosphonate-related Osteonecrosis of the Jaw. J. ZUSTIN, D. RESKE, T.A. ZRNC, M. HEILAND, H.A. SCHEUER, A.T. ASSAF, R.E. FRIEDRICH (Hamburg, Germany) .................................................................................................................. 125

Review: Vitamin D3 Deficiency Results in Dysfunctions of Immunity with Severe Fatigue and Depression in a Variety of Diseases. A.D. HÖCK (Cologne, Germany) .................................................................................................................. 133